Antibiotic Resistance

By the end of this lecture you should be able to

 formulate treatment strategies to reduce the development of antibiotic resistance in the animals you treat and their contacts.

Every time you use an antibiotic you exert selection pressure for resistance on pathogens and commensals

4 yr old bull terrier

- · scratching ears
- · previously treated

broad spec rum an ibio ics s eroids acaricides



resistance

- · in the animal being treated
- · in contact animals
- · in the owner
- in the environment / NZ population

resistance mechanisms

- · drug does not reach its target
- -Pseudomonas
- · drug is inactivated
- -Staph aureus
- -E.coli
- · target is changed
- -MRSA
- -streps

resistance

- · intrinsic
- · acquired

resistance genes

- chromosomes
- plasmids
- transposons
- · integrons
- · gene cassettes

acquired resistance

· conjugation

coliforms

cocci

transduction

S aphs

transformation

cocci?

resistance

- pathogens
- · commensals

human pathogens



· MRSA

-Methicillin resistant Staph aureus

· VRE

 Vancomycin resistant enterococci

| - | | |
|---|--|--|
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| - | | |
| - | | |
| | | |
| - | | |
| - | | |
| - | | |
| - | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

MRSA

- 14% SA isolates 2001
- · Western Samoan phage pattern
- -39% MRSA isolates 2001
- -community acquired
- -Pacific islanders
- -Auckland
- · epidemic MRSA 15
- -40% MRSA isolates 2001
- -from UK
- -acquired in hospital

MRSA 2002

· EMRSA 15 (UK)

-67.5% isolates

· AKh4 (Aus)

-12.3%

· WR/AK1


-7.1%


· WSPP (Samoa)

-2.1%

EMRSA 16 (UK)

-1.9%





VISA

· vancomycin intermediate Staphylococcus aureus

1-2 isola es per year MRSA pa ien s rea ed wi h vancomycin

VRE

- 15 human isolates in NZ so far
- · chickens in Otago

animal Staph aureus

· more resistant than human to

clindamycin / lincomycin co- rimoxazole fluoroquinolones gen amicin e racyclines

animal Staph aureus

· fluoroquinolone resistance

1999 - 0% 2000 - 6 6% 2001 - 12 5% 2002 - s opped moni oring mos ly dogs

food poisoning

· Salmonella spp (DT104)

rare in NZ

• 39 human & 3 animal isolates 1992 - 2001

- Campylobacter
- · E.coli O157

92 cases NZ 2005

· (Shigella)

fluoroquinolone resistance


- · Salmonella spp (DT104)
- NZ 1998 0%
- Campylobacter
- -no figures
- · E.coli (all)
- -animals 2000/1 2.4%, 1999 0.9% · 2001 4 3% dog isolates
- people 2000 1.3%
- · (Shigella)

ESBLs

- extended spectrum beta lactamase producing coliforms
- · emerged in Hawke's bay
- · now in Auckland
- · resistant to cephalosporins

ve erinary use of cephalosporins???

23



ТВ

- 2002 0.6% MDR, 13% single drug resistant
- most cases in people born overseas


TB drugs

- · rifampicin
- clarithromycin / azithromycin
- ethambutol
- · isoniazid
- pyrazinamide
- streptomycin

veterinary pathogens

· Pseudomonas aeruginosa

large genome
lo s of drug efflux pumps
lo s of redundan sys ems
common af er inappropria e an ibio ics
causes problems in people oo



controlling resistance

- use drugs to which significant resistance is unlikely to develop
- · infection control



4 yr old bull terrier

- · scratching ears
- · previously treated


broad spec rum an ibio ics s eroids acaricides



What do you do?

antibiotic treatment

- are the bacteria sensitive to the drug?
- does the drug get to where the bacteria are?
- is significant resistance likely to develop?





What do you do?

- · check for generalised skin disease
- · culture and sensitivity?
- · flush and check ear
- · parenteral antibiotics?
- parenteral steroids?
- · non-antibiotic treatment?
- · alter environment?

reducing resistance

- Choose a drug on resistance testing, where practicable.
- · Use narrow spectrum antimicrobials whenever possible.
- · Use the full effective dose for as short a period as possible.
- · Isolate the patient (and wash your hands / gumboots).
- Use antibacterials not prone to producing resistance.
- Restrict the prophylactic use of antimicrobials to high risk patients only.
- In chronic care patients, regularly (but not frequently) change antimicrobial drugs.
- With aminoglycosides, use the longest effective dosage interval.